16 completed, 3 terminated, 2 unknown, 1 not yet recruiting. 23 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 16, Terminated 3, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Livedoid Vasculopathy: new trials by email Literature Review of Livedoid Vasculopathy trials Research Report on Livedoid Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | Liquidia Technologies, Inc. | 75 | 2026-10-26 | 2026-08-07 |
| Treatment of Frostbite Sequelae With Botulinum Toxin A Botuinum toxin - Cold Hypersensitivity, Vascular System Injuries | Phase 2 | Withdrawn | University Hospital of North Norway | 2022-11-01 | 2024-06-14 | |
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis Temanogrel, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Terminated | Pfizer | 13 | 2021-11-03 | 2023-12-22 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Civi Biopharma, Inc. | 34 | 2019-03-07 | 2025-05-25 |
| CSL Behring Sclero XIII Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride - Systemic Sclerosis | Phase 2 | Unknown | University College, London | 26 | 2015-09-01 | 2016-05-30 |
| Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Neovasculgen - Secondary Raynaud's Phenomenon | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 30 | 2015-03-01 | 2015-02-05 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Alprostadil, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | 35 | 2014-11-01 | 2016-03-22 |
| Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Selexipag, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Actelion | 74 | 2014-10-31 | 2026-06-03 |
| "As Required" Oral Sildenafil in Raynaud's Phenomenon Sildenafil 40 mg, Sildenafil 80 mg, Placebo - Raynaud's Phenomenon | Phase 2 / Phase 3 | Completed | University Hospital, Grenoble | 41 | 2013-11-01 | 2016-01-18 |
| Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Riociguat (Adempas, BAY63-2521), Placebo - Raynaud Disease | Phase 2 | Completed | Bayer | 23 | 2013-10-01 | 2014-06-16 |
| A Two-Part Study of BOTOX® Therapy for Ischemic Digits onabotulinum toxin type-A - Raynaud's Disease | Phase 2 | Completed | Southern Illinois University | 48 | 2011-05-01 | 2019-01-08 |
| Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon ORM-12471 30mg, ORM-12471, placebo - Raynaud's Phenomenon | Phase 2 | Terminated | Orion Corporation, Orion Pharma | 15 | 2011-03-01 | 2014-06-27 |
| Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Udenafil or Amlodipine - Raynaud Phenomenon | Phase 2 / Phase 3 | Completed | Seoul National University Hospital | 29 | 2011-01-01 | 2012-12-11 |
| PF-00489791 For The Treatment Of Raynaud's PF-00489791 - Raynaud's Disease, Peripheral Vascular Disease | Phase 2 | Completed | Pfizer | 243 | 2010-08-04 | 2018-05-16 |
| Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease SLx-2101, Placebo - Raynaud's Disease | Phase 2 | Completed | Response Pharmaceuticals | 17 | 2007-06-01 | 2023-11-18 |
| Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Nitroglycerin - Raynaud's Disease | Phase 2 | Completed | MediQuest Therapeutics | 15 | 2007-05-01 | 2007-12-24 |
| Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome vardenafil, Placebo - Raynaud Syndrome | Phase 2 / Phase 3 | Completed | University of Cologne | 57 | 2006-11-01 | 2011-02-08 |
| Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon MQX-503 - Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma | Phase 2 | Completed | MediQuest Therapeutics | 15 | 2006-07-01 | 2007-05-30 |
Showing 20 of 23. Sign in to see all of them.
Raynaud Disease (23) · Scleroderma, Systemic (12) · Scleroderma, Diffuse (5) · Peripheral Vascular Diseases (2) · Autoimmune Diseases (1) · CREST Syndrome (1) · Cold Hypersensitivity (1) · Ischemia (1) · Neuralgia (1) · Sensation Disorders (1) · Signs and Symptoms (1) · Vascular System Injuries (1) · digital ulcers (1)
Cardiovascular Diseases (23) · Embolism and Thrombosis (23) · Skin Diseases (23) · Skin Diseases, Vascular (23) · Skin and Connective Tissue Diseases (23) · Thrombosis (23) · Vascular Diseases (23) · Peripheral Vascular Diseases (21) · Connective Tissue Diseases (15) · Pathological Conditions, Signs and Symptoms (3) · Scleroderma, Systemic (3) · Calcinosis (1) · Calcium Metabolism Disorders (1) · Deglutition Disorders (1)
Botulinum Toxins, Type A (2) · Nitroglycerin (2) · APD791 (1) · Alprostadil (1) · Amlodipine (1) · Factor VIII (1) · Factor XIII (1) · Ginkgo Extract (1) · Ginkgo biloba extract (1) · Iloprost (1) · PF-00489791 (1) · Saline Solution (1) · Sildenafil Citrate (1) · Sodium Chloride (1) · Tadalafil (1)
MediQuest Therapeutics (3) · Pfizer (2) · Actelion (1) · Artgen Biotech (1) · Bayer (1) · Civi Biopharma, Inc. (1) · Jose Soberon, MD (1) · Liquidia Technologies, Inc. (1) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1) · Orion Corporation, Orion Pharma (1) · Response Pharmaceuticals (1) · Seoul National University Hospital (1) · Southern Illinois University (1) · University College, London (1) · University Hospital of North Norway (1)
United States (10) · Germany (5) · United Kingdom (5) · France (2) · South Korea (2) · Canada (1) · Colombia (1) · Czechia (1) · Hungary (1) · Mexico (1) · Netherlands (1) · Norway (1) · Poland (1) · Russia (1) · Spain (1)
Ariane Herrick, MD (1) · Ariane L Herrick, MB,ChB, MD (1) · Arne J Norheim, PhD (1) · Barbara Troupin, MD, MBA (1) · Carin Dugowson, MD, MPH (1) · Christopher Denton, PhD (1) · Eun Bong Lee, MD PhD (1) · Eun Young Lee, MD PhD (1) · Jin Kyun Park, MD (1) · Jose Soberon, MD (1) · Laura K Hummers, MD (1) · Lee Shapiro, MD (1)
PMID 19194764, PMID 19734516, PMID 20627413, PMID 21868066, PMID 22370242, PMID 23370086, PMID 24352340, PMID 24489014, PMID 26808752, PMID 28452678, PMID 28509693, PMID 29037377, PMID 29193819, PMID 30383134, PMID 33998674, PMID 35894657, PMID 37929840
2005 (1), 2014 (1), 2019 (1)